AlphAIAlphAI — Financial news for AI agents
gurufocus.com$XP

XP Maintains Buy Rating -- Price Target Raised to $37.00 by UBS

UBS raised its price target for XP Inc. from $25.00 to $37.00, maintaining a Buy rating. The stock is currently trading at $30.60, which is 36.1% above its GF Value™ of $22.48, according to GuruFocus. XP has a GF Score™ of 87/100, indicating strong performance, but also shows significant insider selling.

Original reporting
gurufocus.com
Published Oct 8, 2026, 6:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 7:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$XP
Bullish
high confidence
Mentioned
$XP
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$XPBullishMed
01

Why it matters

The UBS rating upgrade provides a fresh catalyst that could attract new buying, but insider sell‑off and valuation premium temper enthusiasm.

02

Market read

Analyst upgrade is a primary corporate event that may move XP's share price in the short term.

03

What to watch

Recent insider selling of $2.4 M could signal downside risk despite the upgrade.

Relevance 7/10Novelty 7/10Timing: today

Background

XP Inc. is a technology-driven financial services platform in Brazil with a market cap of ~$15.8 B.

Company-level read

Ticker impact

$XPBullishHigh confidence
Context

UBS maintains Buy rating on XP and raises price target from $25 to $37, indicating fresh analyst upgrade.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The rating change is a primary disclosure and the target increase is sizable (48%).

Market effects

Sector

May lift sentiment in Brazil's financial services sector.

Regional

Potentially supportive for broader Latin American equities.

Global

Limited to investors focused on emerging market financial stocks.

Counterpoint

What could challenge this read

The stock appears overvalued at $30.60 versus intrinsic $22.48, suggesting caution.

Key entities

  • company
    XP Inc.

    Brazilian financial services platform listed on NYSE under ticker XP.

  • analyst_firm
    UBS

    Provided the rating upgrade and new price target.

Read at source← All news

Related articles

$XPMed

Morgan Stanley cuts XP Inc. stock rating on Brazil outlook concerns

Morgan Stanley downgraded XP Inc. (NASDAQ:XP) to Equalweight, cutting its price target to $19.00 from $23.00. Analyst Jorge Kuri cited Brazil's post-election outlook as undermining the lower-rates thesis. The stock has fallen 45% in a week, trading at $16.09. Morgan Stanley also downgraded B3 (B3SA3.SA) to Equalweight. XP's Q2 2026 earnings beat estimates, with adjusted EPS of $2.67 and revenue of $4.88 billion, but the stock declined due to investor caution.

investing.com
$XPHigh

Why is Xp stock plummeting 45% today?

Xp Inc. stock dropped 45.3% in pre-market trading to $16.63, driven by corporate governance concerns and a worsening macroeconomic environment. The decline follows leadership changes and a reduction in stake by institutional investor Assenagon. The stock had previously gained significantly year-to-date, reaching a 52-week high of $32.73. The broader financial sector also faced selling pressure due to rising oil prices and inflation fears.

investing.com
$XPMed

Morgan Stanley Upgrades Brazil Stocks to Buy

Morgan Stanley upgraded Brazilian stocks to overweight, citing potential 15-20% gains by 2026. The bank favors domestic-focused companies like B3, XP, and Nubank. Foreign investors injected R$10.06B into Brazilian stocks on Monday, the largest daily inflow of 2026.

riotimesonline.com